Plitidepsin May Be Candidate Therapy For Patients Hospitalized With Moderate COVID-19, Study Suggests

Infectious Disease Advisor (10/2, Basilio) reports, “Plitidepsin (Aplidin) may be considered a candidate therapy for patients hospitalized with moderate COVID-19, especially those who require supplemental oxygen therapy, according to study results.” Treatment-emergent adverse events “of special interest were reported by 34.9%, 37.3%, and 27.7% of patients in the plitidepsin 2.5 mg, plitidepsin 1.5 mg, and control arms, respectively.” The findings were published in Clinical Infectious Diseases.